PRGN-2012 is under clinical development by Precigen and currently in Phase II for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma). According to GlobalData, Phase II drugs for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PRGN-2012 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRGN-2012 overview
PRGN-2012 is under development for the treatment of recurrent respiratory papillomatosis (RRP) caused by human papillomavirus (HPV) type 6 (HPV 6) or HPV type 11 (HPV 11). It is administered through subcutaneous route. It comprises of adenoviral vector expressing an antigen (gene). The drug candidate is being developed based on the AdenoVerse technology platform and gorilla adenovector technology.
Precigen overview
Precigen is a clinical-stage biotechnology company that discovers, develops and commercializes next-generation gene and cell therapies to target diseases in immuno-oncology, autoimmune disorders and infections. The company’s clinical pipeline includes AG019, PRGN-3005, PRGN-3006, PRGN-3007, PRGN-2009 and PRGN-2012 for the indications of type 1 diabetes, ovarian cancer, acute myeloid leukemia and myelodysplastic syndromes, hematological and solid tumors, recurrent respiratory papillomatosis. Precigen preclinical pipeline includes PRGN-5001, PRGN-2010, PRGN-2011, PRGN-2013 and AG017, among others for solid tumors and celiac disease. The company utilizes therapeutic platforms including UltraCAR-T, AdenoVerse therapies, ActoBiotics, multifunctional therapeutics, UltraVector, AdenoVerse, AttSite, UltraPorator and RheoSwitch, among others. The company operates in the US and Belgium. Precigen is headquartered in Germantown, Maryland, the US.
For a complete picture of PRGN-2012’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
